|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:CCND2-CCND2 (FusionGDB2 ID:HG894TG894) |
Fusion Gene Summary for CCND2-CCND2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: CCND2-CCND2 | Fusion gene ID: hg894tg894 | Hgene | Tgene | Gene symbol | CCND2 | CCND2 | Gene ID | 894 | 894 |
Gene name | cyclin D2 | cyclin D2 | |
Synonyms | KIAK0002|MPPH3 | KIAK0002|MPPH3 | |
Cytomap | ('CCND2')('CCND2') 12p13.32 | 12p13.32 | |
Type of gene | protein-coding | protein-coding | |
Description | G1/S-specific cyclin-D2 | G1/S-specific cyclin-D2 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | P30279 | P30279 | |
Ensembl transtripts involved in fusion gene | ENST00000261254, ENST00000541542, | ENST00000261254, ENST00000541542, | |
Fusion gene scores | * DoF score | 5 X 6 X 2=60 | 4 X 6 X 3=72 |
# samples | 6 | 6 | |
** MAII score | log2(6/60*10)=0 | log2(6/72*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CCND2 [Title/Abstract] AND CCND2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | CCND2(4411335)-CCND2(4413194), # samples:1 CCND2(4410395)-CCND2(4411810), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CCND2 | GO:0001934 | positive regulation of protein phosphorylation | 8114739 |
Hgene | CCND2 | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 8114739 |
Tgene | CCND2 | GO:0001934 | positive regulation of protein phosphorylation | 8114739 |
Tgene | CCND2 | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 8114739 |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for CCND2-CCND2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for CCND2-CCND2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for CCND2-CCND2 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:4411335/:4413194) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
CCND2 | CCND2 |
FUNCTION: Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D2/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex (By similarity). {ECO:0000250}. | FUNCTION: Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D2/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex (By similarity). {ECO:0000250}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CCND2-CCND2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for CCND2-CCND2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CCND2-CCND2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CCND2-CCND2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | CCND2 | C1863924 | Megalanecephaly Polymicrogyria-Polydactyly Hydrocephalus Syndrome | 2 | CTD_human;ORPHANET |
Hgene | CCND2 | C0007102 | Malignant tumor of colon | 1 | CTD_human |
Hgene | CCND2 | C0009375 | Colonic Neoplasms | 1 | CTD_human |
Hgene | CCND2 | C0009402 | Colorectal Carcinoma | 1 | CTD_human |
Hgene | CCND2 | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
Hgene | CCND2 | C0009451 | Communicating Hydrocephalus | 1 | CTD_human |
Hgene | CCND2 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Hgene | CCND2 | C0016059 | Fibrosis | 1 | CTD_human |
Hgene | CCND2 | C0018800 | Cardiomegaly | 1 | CTD_human |
Hgene | CCND2 | C0020255 | Hydrocephalus | 1 | CTD_human |
Hgene | CCND2 | C0020256 | Congenital Hydrocephalus | 1 | CTD_human |
Hgene | CCND2 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
Hgene | CCND2 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
Hgene | CCND2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | CCND2 | C0036341 | Schizophrenia | 1 | PSYGENET |
Hgene | CCND2 | C0151744 | Myocardial Ischemia | 1 | CTD_human |
Hgene | CCND2 | C0152427 | Polydactyly | 1 | GENOMICS_ENGLAND |
Hgene | CCND2 | C0220697 | POLYDACTYLY, POSTAXIAL | 1 | CTD_human |
Hgene | CCND2 | C0221355 | Macrocephaly | 1 | CTD_human |
Hgene | CCND2 | C0270720 | Hydrocephalus Ex-Vacuo | 1 | CTD_human |
Hgene | CCND2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
Hgene | CCND2 | C0477432 | Post-Traumatic Hydrocephalus | 1 | CTD_human |
Hgene | CCND2 | C0549423 | Obstructive Hydrocephalus | 1 | CTD_human |
Hgene | CCND2 | C0919267 | ovarian neoplasm | 1 | CTD_human |
Hgene | CCND2 | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human |
Hgene | CCND2 | C1383860 | Cardiac Hypertrophy | 1 | CTD_human |
Hgene | CCND2 | C1531647 | Cerebral ventriculomegaly | 1 | CTD_human |
Hgene | CCND2 | C1623038 | Cirrhosis | 1 | CTD_human |
Hgene | CCND2 | C1845668 | Perisylvian syndrome | 1 | CTD_human |
Hgene | CCND2 | C1868120 | POSTAXIAL POLYDACTYLY, TYPE B | 1 | CTD_human |
Hgene | CCND2 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
Hgene | CCND2 | C1879677 | Alcohol Toxicity | 1 | PSYGENET |
Hgene | CCND2 | C2936718 | Fetal Cerebral Ventriculomegaly | 1 | CTD_human |
Hgene | CCND2 | C2936786 | Aqueductal Stenosis | 1 | CTD_human |
Hgene | CCND2 | C3887487 | Postaxial polydactyly type A | 1 | CTD_human |
Hgene | CCND2 | C4014742 | MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 3 | 1 | GENOMICS_ENGLAND;UNIPROT |
Hgene | CCND2 | C4282400 | Polydactyly, Postaxial, Type A1 | 1 | CTD_human |
Tgene | C1863924 | Megalanecephaly Polymicrogyria-Polydactyly Hydrocephalus Syndrome | 2 | CTD_human;ORPHANET | |
Tgene | C0007102 | Malignant tumor of colon | 1 | CTD_human | |
Tgene | C0009375 | Colonic Neoplasms | 1 | CTD_human | |
Tgene | C0009402 | Colorectal Carcinoma | 1 | CTD_human | |
Tgene | C0009404 | Colorectal Neoplasms | 1 | CTD_human | |
Tgene | C0009451 | Communicating Hydrocephalus | 1 | CTD_human | |
Tgene | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human | |
Tgene | C0016059 | Fibrosis | 1 | CTD_human | |
Tgene | C0018800 | Cardiomegaly | 1 | CTD_human | |
Tgene | C0020255 | Hydrocephalus | 1 | CTD_human | |
Tgene | C0020256 | Congenital Hydrocephalus | 1 | CTD_human | |
Tgene | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human | |
Tgene | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human | |
Tgene | C0033578 | Prostatic Neoplasms | 1 | CTD_human | |
Tgene | C0036341 | Schizophrenia | 1 | PSYGENET | |
Tgene | C0151744 | Myocardial Ischemia | 1 | CTD_human | |
Tgene | C0152427 | Polydactyly | 1 | GENOMICS_ENGLAND | |
Tgene | C0220697 | POLYDACTYLY, POSTAXIAL | 1 | CTD_human | |
Tgene | C0221355 | Macrocephaly | 1 | CTD_human | |
Tgene | C0270720 | Hydrocephalus Ex-Vacuo | 1 | CTD_human | |
Tgene | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human | |
Tgene | C0477432 | Post-Traumatic Hydrocephalus | 1 | CTD_human | |
Tgene | C0549423 | Obstructive Hydrocephalus | 1 | CTD_human | |
Tgene | C0919267 | ovarian neoplasm | 1 | CTD_human | |
Tgene | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human | |
Tgene | C1383860 | Cardiac Hypertrophy | 1 | CTD_human | |
Tgene | C1531647 | Cerebral ventriculomegaly | 1 | CTD_human | |
Tgene | C1623038 | Cirrhosis | 1 | CTD_human | |
Tgene | C1845668 | Perisylvian syndrome | 1 | CTD_human | |
Tgene | C1868120 | POSTAXIAL POLYDACTYLY, TYPE B | 1 | CTD_human | |
Tgene | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human | |
Tgene | C1879677 | Alcohol Toxicity | 1 | PSYGENET | |
Tgene | C2936718 | Fetal Cerebral Ventriculomegaly | 1 | CTD_human | |
Tgene | C2936786 | Aqueductal Stenosis | 1 | CTD_human | |
Tgene | C3887487 | Postaxial polydactyly type A | 1 | CTD_human | |
Tgene | C4014742 | MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 3 | 1 | GENOMICS_ENGLAND;UNIPROT | |
Tgene | C4282400 | Polydactyly, Postaxial, Type A1 | 1 | CTD_human |